Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Canon Medical Diagnostics Corporation has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit. POHNERT, STEVEN C is the busiest examiner, with 1 busiest examiner pending action. This single action represents the entire current workload for the company at the patent office.
With 1 pending office action total, the entire current prosecution for the company is handled by this single examiner. The work is concentrated within one specific art unit for the technology area, suggesting a highly targeted patenting effort. The role of POHNERT, STEVEN C is central, as this individual is responsible for the review of the company's only pending matter. Practitioners should note that the prosecution strategy is currently focused on a single examiner and a single specialized unit within the Biotechnology & Pharmaceuticals field.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| POHNERT, STEVEN C | 1 | 12.5% | +18.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18806201 | Method for Measuring Fibroblast Growth Factor-23 and Reagent Therefor | POHNERT, STEVEN C | 5d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18806201 | Method for Measuring Fibroblast Growth Factor-23 and Reagent Therefor | POHNERT, STEVEN C | 5d overdue |
| Art Unit | Apps |
|---|---|
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18806201 | Method for Measuring Fibroblast Growth Factor-23 and Reagent Therefor | POHNERT, STEVEN C | 1683 | §112Other | Final Rejection | 5d overdue | Pending | Aug 15, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCanon Medical Diagnostics Corporation has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Steven C Pohnert has the most, with 1 of Canon Medical Diagnostics Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.